JPMorgan Chase & Co. Buys 124,133 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

JPMorgan Chase & Co. boosted its position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 498.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 149,045 shares of the company's stock after purchasing an additional 124,133 shares during the period. JPMorgan Chase & Co. owned about 0.22% of Perspective Therapeutics worth $475,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of CATX. Barclays PLC increased its holdings in shares of Perspective Therapeutics by 587.9% during the 3rd quarter. Barclays PLC now owns 114,075 shares of the company's stock worth $1,523,000 after acquiring an additional 97,493 shares during the last quarter. Taylor & Morgan Wealth Management LLC raised its position in shares of Perspective Therapeutics by 86.7% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 56,000 shares of the company's stock valued at $179,000 after purchasing an additional 26,000 shares during the period. Trueblood Wealth Management LLC boosted its holdings in shares of Perspective Therapeutics by 37.0% during the 4th quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company's stock worth $71,000 after buying an additional 6,000 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Perspective Therapeutics by 41.3% during the 4th quarter. SG Americas Securities LLC now owns 26,088 shares of the company's stock worth $83,000 after buying an additional 7,627 shares during the period. Finally, Wealth Effects LLC grew its stake in Perspective Therapeutics by 186.8% in the 4th quarter. Wealth Effects LLC now owns 38,000 shares of the company's stock valued at $121,000 after buying an additional 24,750 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company's stock.

Insider Activity at Perspective Therapeutics

In related news, Director Robert F. Williamson III acquired 38,145 shares of the stock in a transaction dated Monday, March 31st. The stock was bought at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the completion of the transaction, the director now directly owns 108,982 shares of the company's stock, valued at $233,221.48. The trade was a 53.85 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Johan M. Spoor purchased 22,026 shares of the stock in a transaction on Friday, March 28th. The shares were purchased at an average price of $2.24 per share, with a total value of $49,338.24. Following the acquisition, the chief executive officer now owns 59,383 shares in the company, valued at approximately $133,017.92. The trade was a 58.96 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 115,696 shares of company stock valued at $256,344 in the last 90 days. 3.52% of the stock is owned by corporate insiders.

Analyst Ratings Changes

CATX has been the topic of several research reports. Lifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. Wedbush reissued an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Wednesday, March 26th. Royal Bank of Canada lowered their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating on the stock in a report on Thursday, March 27th. Brookline Capital Management upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Truist Financial lowered their price objective on Perspective Therapeutics from $21.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, April 7th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $12.75.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock traded up $0.09 during mid-day trading on Friday, reaching $2.56. The company had a trading volume of 713,082 shares, compared to its average volume of 1,026,178. The business has a fifty day simple moving average of $2.28 and a 200 day simple moving average of $4.38. Perspective Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $19.05.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.